PT - JOURNAL ARTICLE AU - Kwon, Soonwook AU - Kim, Bongseong AU - Han, Kyung-Do AU - Jung, Wonyoung AU - Cho, Eun Bin AU - Shin, Dong Wook AU - Min, Ju-Hong TI - Increased Risk of Ischemic Stroke in Amyotrophic Lateral Sclerosis: A Nationwide Cohort Study in South Korea AID - 10.1101/2023.08.11.23294006 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.11.23294006 4099 - http://medrxiv.org/content/early/2023/08/16/2023.08.11.23294006.short 4100 - http://medrxiv.org/content/early/2023/08/16/2023.08.11.23294006.full AB - Background We investigated the risk of ischemic stroke in ALS and analyzed the effect of ALS-related physical disability using the Korean National Health Insurance Service database.Methods A total of 2,252 ALS patients diagnosed between January 1, 2012, and December 31, 2015, and 1:10 age- and sex-matched control populations were included. After selection of cases that participated in the national health check-up programs, 659 ALS patients and 10,927 non-ALS participants were remained. Newly developing ischemic stroke as primary outcome was also defined by the ICD code and the incidence probability was assessed using by the Kaplan– Meier method during the follow-up duration. A Cox hazard regression model was used to examine the hazard ratios (HRs) for ischemic stroke in ALS after adjusting for potential confounders.Results ALS patients were younger than the control group (60.3 ± 10.2 years vs. 61.4 ± 10.5 years, p = 0.008), and the proportion of male patients was similar between the two groups (61.0% vs. 62.5%, p = 0.447). ALS patients were more likely to have a lower body mass index (23.1 ± 2.92 vs. 24.0 ± 3.00, p < 0.001) and be non-drinkers (64.2% vs. 57.4%, p = 0.002) than the controls. In ALS patients, the incidence of ischemic stroke was 7.8 per 1,000 person-years, and the adjusted HR of ischemic stroke was 3.67 (95% confidence interval 2.02−6.67) compared with the control group. The risk of ischemic stroke did not differ by the presence of disability in ALS patients.Conclusions Our findings suggest that ALS patients face increased risk of ischemic stroke compared with controls, but the risk did not differ by the presence of disability in ALS.Competing Interest StatementJu-Hong Min has lectured, consulted, and received honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Sanofi Genzyme, Teva-Handok, UCB, Samsung Bioepis, Mitsubishi Tanabe Pharma, and Roche. Ju-Hong Min received a National Research Foundation of Korea grant and an SMC Research and Development Grant. The other authors report no disclosures relevant to the manuscript.Clinical TrialThis study is not clinical tirals.Funding StatementThis research was partially supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI20C1073).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Samsung Medical Center (File No. SMC-2020-12-108). The review board waived the requirement for written informed consent because publicly open and anonymous data were used for the analysis and retrospective features.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available upon reasonable request. The data set analyzed in this study is not publicly available because of restricted access, but further information about the data set is available from the corresponding author on reasonable request.